Business Context and Reporting Period
PharmaCyte Biotech, Inc., a Nevada corporation, filed this Form 8-K on January 7, 2016, to report the entry into a Material Definitive Agreement and the unregistered sale of equity securities. The company is headquartered in Silver Spring, Maryland.
Key Financial Metrics and Transaction Details
This filing details a private placement transaction rather than standard periodic financial results. Key metrics from the transaction include:
- Aggregate Gross Proceeds: $1.02 million.
- Investors: Berkshire Capital Management Co., Inc. and SPYR, Inc. (current stockholders).
- Common Stock Issued: 17 million shares at $0.06 per share.
- Warrants Issued: 17 million warrants with a five-year term.
- Warrant Exercise Price: $0.12 per share.
- Warrant Features: Cashless exercise feature; no registration rights.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in the company's capital base through the issuance of 17 million shares of common stock and 17 million warrants. This transaction represents a significant dilution event for existing shareholders, as the issuance price of $0.06 per share was set for the private placement.
Outlook, Risks, and Contingencies
Regulatory Status: The securities were sold pursuant to Section 4(a)(2) of the Securities Act and Regulation D as "restricted securities." They are not registered and may not be resold unless an effective registration statement is filed or an exemption opinion is obtained.
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations or financial performance beyond the description of the transaction.
Risks: The primary risk highlighted is the restricted nature of the securities sold, limiting their immediate liquidity in the secondary market.
Investor Verification Checklist
- Verify the current share count and the impact of the 17 million new shares on ownership dilution.
- Confirm the cashless exercise mechanics of the warrants and their potential future dilution impact.
- Review the company's most recent 10-K or 10-Q to assess liquidity needs, as this filing only discloses the $1.02 million inflow.
- Check for any subsequent filings regarding the use of proceeds from this private placement.